Skip to content

Serge Messerlian

Operating Partner, DCVC Bio

Serge brings significant experience in the life science industry across a range of roles and therapeutic areas, including hematology, oncology, immunology, and rare diseases. 

Before joining DCVC Bio, Serge was CEO of Teon Ther­a­peu­tics, an immuno-oncology biotech. Prior to that, as President of Janssen Oncology, a division of the Janssen Phar­ma­ceu­tical Companies of Johnson & Johnson, he set the strategic direction for the orga­ni­za­tion, its key brands, and pipeline programs across hematology and solid tumors, as well as platforms including cell therapies and bi-specifics. He also held executive leadership roles at Johnson & Johnson’s Actelion, Baxalta, and Baxter International. 

Serge holds a bachelor’s degree in physiology and biotech­nology and a master’s degree in human genetics, both from McGill University, and an MBA from the University of Toronto.